The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group. Headache. 2024; 64(8):912-930.
Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments. Headache. 2023; 63(6):805-812.
Multimodal Assessment of Medication Adherence Among Youth With Migraine: An Ancillary Study of the CHAMP Trial. Journal of Pediatric Psychology. 2022; 47(4):376-387.
Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. Cephalalgia. 2022; 42(1):44-52.
Prevalence of Headache Days and Disability 3 Years After Participation in the Childhood and Adolescent Migraine Prevention Medication Trial. JAMA Network Open. 2021; 4(7):e2114712.
Identification of neural and psychophysical predictors of headache reduction after cognitive behavioral therapy in adolescents with migraine. Pain. 2021; 162(2):372-381.
Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine in Children and Adolescents. Headache. 2020; 60(6):1165-1182.
Treatment Adherence in Child and Adolescent Chronic Migraine Patients: Results From the Cognitive-Behavioral Therapy and Amitriptyline Trial. Clinical Journal of Pain. 2017; 33(10):892-898.
Treatment of Pediatric Migraine. New England Journal of Medicine. 2017; 376(14):1388-1389.
The Childhood and Adolescent Migraine Prevention (CHAMP) Study: "What Do We Do Now?". Headache. 2017; 57(2):180-183.
Trial of Amitriptyline, Topiramate, and Placebo for Pediatric Migraine. New England Journal of Medicine. 2017; 376(2):115-124.
Cognitive Behavioral Therapy plus Amitriptyline for Children and Adolescents with Chronic Migraine Reduces Headache Days to ≤4 Per Month. Headache. 2016; 56(4):711-716.
Behavioral and nutritional treatment for preschool-aged children with cystic fibrosis: a randomized clinical trial. JAMA pediatrics. 2015; 169(5):e150636.
Cognitive-Behavioral Therapy: How Medical Providers Can Increase Patient and Family Openness and Access to Evidence-Based Multimodal Therapy for Pediatric Migraine. Headache. 2015; 55(10):1382-1396.
Logan Wright Award: Team science, team care, team training, and team leadership: my experience. Journal of Pediatric Psychology. 2014; 39(3):277-282.
Cognitive behavioral therapy plus amitriptyline for chronic migraine in children and adolescents: a randomized clinical trial. Journal of the American Medical Association (JAMA). 2013; 310(24):2622-2630.
Building a national headache medicine research network: The BE WELL with Migraine Champion Providers Network™. Headache. 2025.
Smartphone-Based Muscle Relaxation for Migraine in the Emergency Department: A Randomized Clinical Trial. JAMA Network Open. 2025; 8(10):e2534221.
Protocol for a randomized controlled trial evaluating a digital behavioral self-management intervention for adolescent migraine. Applied Nursing Research. 2025; 84:151979.
Behavioral interventions for migraine prevention: A systematic review and meta-analysis. Headache. 2025; 65(4):668-694.
Youth with high-frequency headaches due to migraine are more vulnerable to non-cephalic pain complaints. Headache. 2025; 65(4):655-657.
Single arm feasibility trial of a mobile application for adolescent migraine management. Pain Medicine. 2025; 26(3):170-172.
Elexacaftor/tezacaftor/ivacaftor and mental health: A workshop report from the Cystic Fibrosis Foundation's Prioritizing Research in Mental Health working group. Journal of Cystic Fibrosis. 2025; 24(2):301-309.
Behavior and migraine virtual issue. Headache. 2025; 65(2):203-205.
The impact of neuroscience education therapy, behavioral economics, and digital navigators on patient migraine treatment adherence to a mobile health application: a prospective pilot randomized controlled trial. NPP-Digital Psychiatry and Neuroscience. 2025; 3(1):2.
Characterizing sleep, headache-related disability, and psychological functioning among adolescents with continuous headache: A pilot study from a tertiary clinical setting. Headache. 2025; 65(10):1766-1775.
Headache in Children and Adolescents. In: Swaiman S Pediatric Neurology Principles and Practice. 2025:937-944.e3.
The 2025 Scottsdale Headache Symposium: New beginnings. Headache. 2025; 65(10):1677-1678.
Not their fault: Mental health characteristics of parents with migraine and the migraine status of their children. Headache. 2024; 64(9):1143-1145.
The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group. Headache. 2024; 64(8):912-930.
Clinic-Based Characterization of Adolescents and Young Adults With Migraine: Psychological Functioning, Headache Days, and Disability. Neurology: Clinical Practice. 2024; 14(3):e200294.
Randomized Controlled Trial of a Smartphone-based Preventive Migraine Self-management Program in the Emergency Department Setting: A Promising Teachable Moment (S22.004) Neurology. 2024; 102(7_supplement_1).
Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update. Headache. 2024; 64(4):333-341.
Preliminary prospective observational investigation of clinical outcomes among treatment-seeking youth with continuous headache. Headache. 2024; 64(3):319-322.
The 2024 Scottsdale Headache Symposium: A banner year. Headache. 2024; 64(10):1179-1180.
Commentary: Enhancing Clinical Care for Patients With Early Childhood Concussion. Journal of Pediatric Psychology. 2023; 48(12):982-983.
Melatonin for migraine prevention in children and adolescents: A randomized, double-blind, placebo-controlled trial after single-blind placebo lead-in. Headache. 2023; 63(9):1314-1326.
Characterization of Migraine in Children and Adolescents With Generalized Joint Hypermobility: A Case-Control Study. Neurology: Clinical Practice. 2023; 13(5):e200188.
The 2023 Scottsdale Headache Symposium. Headache. 2023; 63(9):1330-1331.
Impact of preventive pill-based treatment on migraine days: A secondary outcome study of the Childhood and Adolescent Migraine Prevention (CHAMP) trial and a comparison of self-report to nosology-derived assessments. Headache. 2023; 63(6):805-812.
Virtual issue: Recent advances in pediatric headache: Bridging the data gap. Headache. 2023; 63(3):305-306.
Bridging the gap between preclinical scientists, clinical researchers, and clinicians: From animal research to clinical practice. Headache. 2023; 63(1):25-39.
Biopsychosocial treatment response among youth with continuous headache: A retrospective, clinic-based study. Headache. 2023; 63(7):942-952.
New insight into the neural mechanisms of migraine in adolescents: Relationships with sleep. Headache. 2022; 62(6):668-680.
Multimodal Assessment of Medication Adherence Among Youth With Migraine: An Ancillary Study of the CHAMP Trial. Journal of Pediatric Psychology. 2022; 47(4):376-387.
Predictors of Improvement in Pediatric Chronic Migraine: Results from the Cognitive-Behavioral Therapy and Amitriptyline Trial. Journal of Clinical Psychology in Medical Settings. 2022; 29(1):113-119.
Structural lung disease in preschool children with cystic fibrosis: An 18 month natural history study. Journal of Cystic Fibrosis. 2022; 21(2):e165-e171.
Psychological Interventions for Pediatric Headache Disorders: A 2021 Update on Research Progress and Needs. Current Pain and Headache Reports. 2022; 26(1):85-91.
Chapter 13 Acute behavioral headache management ☆. In: Pediatric Headache. Elsevier; 2022:153-159.
Chapter 17 Preventive behavioral headache management ☆. In: Pediatric Headache. Elsevier; 2022:191-204.
Management of Chronic Migraine in Children and Adolescents: Where are We in 2022? Pediatric Health, Medicine and Therapeutics. 2022; 13:309-323.
Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. Cephalalgia. 2022; 42(1):44-52.